Literature DB >> 19484795

Measuring therapeutic alliance between oncologists and patients with advanced cancer: the Human Connection Scale.

Jennifer W Mack1, Susan D Block, Matthew Nilsson, Alexi Wright, Elizabeth Trice, Robert Friedlander, Elizabeth Paulk, Holly G Prigerson.   

Abstract

BACKGROUND: Patients consider their human connection with a physician an important aspect of end-of-life (EOL) care. In this study, the authors sought to develop and validate a measure of therapeutic alliance between patients with advanced cancer and their physicians and to evaluate the effects of therapeutic alliance on EOL experiences and care.
METHODS: The Human Connection (THC) scale was developed to measure the extent to which patients felt a sense of mutual understanding, caring, and trust with their physicians. The scale was administered to 217 patients with advanced cancer along with measures of attributes that have been related hypothetically to therapeutic alliance, including emotional acceptance of terminal illness. EOL outcomes in 90 patients who died during the study also were examined.
RESULTS: The 16-item THC questionnaire was consistent internally (Cronbach alpha = .90) and valid based on its expected positive association with emotional acceptance of terminal illness (r = .31; P < .0001). THC scores were related inversely to symptom burden (r = -.19; P = .006), functional status (Karnofsky performance status; r = .22; P = .001), and mental illness (THC score: 50.69 for patients with any Diagnostic and Statistical Manual [DSM] diagnosis vs 55.22 for patients with no DSM diagnosis; P = .03). THC scores were not associated significantly with EOL discussions (P = .68). Among the patients who died, EOL intensive care unit (ICU) care was associated inversely with therapeutic alliance (THC score: 46.5 for patients who received ICU care vs 55.5 for patients without ICU care; P = .002), so that patients with higher THC scores were less likely to spend time in the ICU during the last week of life.
CONCLUSIONS: The THC scale is a valid and reliable measure of therapeutic alliance between patients with advanced cancer and their physicians. In addition, there was no evidence to suggest that EOL discussions harm patients' therapeutic alliance. A strong therapeutic alliance was associated with emotional acceptance of a terminal illness and with decreased ICU care at the EOL among patients with advanced cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19484795      PMCID: PMC2771331          DOI: 10.1002/cncr.24360

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review.

Authors:  D J Martin; J P Garske; M K Davis
Journal:  J Consult Clin Psychol       Date:  2000-06

2.  The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability.

Authors:  J B Williams; M Gibbon; M B First; R L Spitzer; M Davies; J Borus; M J Howes; J Kane; H G Pope; B Rounsaville
Journal:  Arch Gen Psychiatry       Date:  1992-08

3.  Validity of the McGill Quality of Life Questionnaire in the palliative care setting: a multi-centre Canadian study demonstrating the importance of the existential domain.

Authors:  S R Cohen; B M Mount; E Bruera; M Provost; J Rowe; K Tong
Journal:  Palliat Med       Date:  1997-01       Impact factor: 4.762

4.  Pretreatment expectations, interpersonal functioning, and symptoms in the prediction of the therapeutic alliance across supportive-expressive psychotherapy and cognitive therapy.

Authors:  M B Connolly Gibbons; P Crits-Christoph; C de la Cruz; J P Barber; L Siqueland; M Gladis
Journal:  Psychother Res       Date:  2003-03

5.  Creating enduring change: demonstrating the long-term impact of a faculty development program in palliative care.

Authors:  Amy M Sullivan; Matthew D Lakoma; J Andrew Billings; Antoinette S Peters; Susan D Block
Journal:  J Gen Intern Med       Date:  2006-09       Impact factor: 5.128

6.  You want to measure coping but your protocol's too long: consider the brief COPE.

Authors:  C S Carver
Journal:  Int J Behav Med       Date:  1997

7.  Communicating prognosis to patients with metastatic disease: what do they really want to know?

Authors:  P N Butow; S Dowsett; R Hagerty; M H N Tattersall
Journal:  Support Care Cancer       Date:  2001-09-07       Impact factor: 3.603

8.  Attitude and self-reported practice regarding prognostication in a national sample of internists.

Authors:  N A Christakis; T J Iwashyna
Journal:  Arch Intern Med       Date:  1998-11-23

9.  Determining the extent of the cancer and clinical planning for cure.

Authors:  D A Karnofsky
Journal:  Cancer       Date:  1968-10       Impact factor: 6.860

10.  'Hitting you over the head': oncologists' disclosure of prognosis to advanced cancer patients.

Authors:  Elisa J Gordon; Christopher K Daugherty
Journal:  Bioethics       Date:  2003-04       Impact factor: 1.898

View more
  64 in total

1.  Factors important to patients' quality of life at the end of life.

Authors:  Baohui Zhang; Matthew E Nilsson; Holly G Prigerson
Journal:  Arch Intern Med       Date:  2012-08-13

2.  Effects of the Values and Options in Cancer Care Communication Intervention on Personal Caregiver Experiences of Cancer Care and Bereavement Outcomes.

Authors:  Paul R Duberstein; Paul K Maciejewski; Ronald M Epstein; Joshua J Fenton; Benjamin Chapman; Sally A Norton; Michael Hoerger; Marsha N Wittink; Daniel J Tancredi; Guibo Xing; Supriya Mohile; Richard L Kravitz; Holly G Prigerson
Journal:  J Palliat Med       Date:  2019-06-25       Impact factor: 2.947

3.  Racial disparities in the outcomes of communication on medical care received near death.

Authors:  Jennifer W Mack; M Elizabeth Paulk; Kasisomayajula Viswanath; Holly G Prigerson
Journal:  Arch Intern Med       Date:  2010-09-27

4.  The lasting impact of the therapeutic alliance: Patient-oncologist alliance as a predictor of caregiver bereavement adjustment.

Authors:  Kelly M Trevino; Paul K Maciejewski; Andrew S Epstein; Holly G Prigerson
Journal:  Cancer       Date:  2015-06-04       Impact factor: 6.860

5.  A study to improve communication between clinicians and patients with advanced heart failure: methods and challenges behind the working to improve discussions about defibrillator management trial.

Authors:  Nathan E Goldstein; Jill Kalman; Jean S Kutner; Erik K Fromme; Mathew D Hutchinson; Hannah I Lipman; Daniel D Matlock; Keith M Swetz; Rachel Lampert; Omarys Herasme; R Sean Morrison
Journal:  J Pain Symptom Manage       Date:  2014-04-21       Impact factor: 3.612

6.  The association between the strength of the working alliance and sharing concerns by advanced cancer patients: a pilot study.

Authors:  Gil Bar-Sela; Sivan Yochpaz; Rachel Gruber; Doron Lulav-Grinwald; Inbal Mitnik; Dan Koren
Journal:  Support Care Cancer       Date:  2015-06-12       Impact factor: 3.603

7.  Impact of Prognostic Discussions on the Patient-Physician Relationship: Prospective Cohort Study.

Authors:  Joshua J Fenton; Paul R Duberstein; Richard L Kravitz; Guibo Xing; Daniel J Tancredi; Kevin Fiscella; Supriya Mohile; Ronald M Epstein
Journal:  J Clin Oncol       Date:  2017-11-17       Impact factor: 44.544

8.  Clinical trial participation among ethnic/racial minority and majority patients with advanced cancer: what factors most influence enrollment?

Authors:  Rachel Jimenez; Baohui Zhang; Steven Joffe; Matthew Nilsson; Lorna Rivera; Jan Mutchler; Christopher Lathan; M Elizabeth Paulk; Holly G Prigerson
Journal:  J Palliat Med       Date:  2013-02-05       Impact factor: 2.947

9.  Accuracy of Oncologists' Life-Expectancy Estimates Recalled by Their Advanced Cancer Patients: Correlates and Outcomes.

Authors:  Jason Lambden; Baohui Zhang; Robert Friedlander; Holly G Prigerson
Journal:  J Palliat Med       Date:  2016-08-30       Impact factor: 2.947

10.  Patient-oncologist alliance, psychosocial well-being, and treatment adherence among young adults with advanced cancer.

Authors:  Kelly M Trevino; Karen Fasciano; Holly G Prigerson
Journal:  J Clin Oncol       Date:  2013-03-25       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.